Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | MMP2 | P08253 | 4/20 | 0.61 |
| ▸ | MMP9 | P14780 | 4/20 | 0.61 |
| ▸ | MMP8 | P22894 | 4/20 | 0.61 |
| ▸ | MMP13 | P45452 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 10/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343727 | 1.00 | NPC1 (0.61) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL6330463 | 0.90 | NPC1 (0.73) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL2361694 | 0.85 | NPBWR1 (0.47) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL20982681 | 0.85 | NPC1 (0.73) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL5566197 | 0.85 | NPC1 (0.78) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL3204647 | 0.84 | RAB9A (0.60) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL15245140 | 0.83 | DGAT1 (0.67) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL6325681 | 0.83 | MAPT (0.66) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL23011274 | 0.81 | RAB9A (0.50) | NPC1MAPTRAB9AMMP2MMP9 | |
| SCHEMBL29848553 | 0.81 | RAB9A (0.50) | NPC1MAPTRAB9AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3515904-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | Centre Leon Berard (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | SIRCAR JAGADISH C | 2005-12-15 | — | — | US | disclosed |
| US-6911462-B2 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| US-6369091-B1 | ANTIALLERGENS | AVANIR PHARMACEUTICALS | 2002-04-09 | — | — | US | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | NPC1 1805/4885MAPT 4242/4885RAB9A 1921/4885 |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPC1 3329/4885MAPT 3023/4885RAB9A 4088/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | NPC1 3255/4885MAPT 2314/4885RAB9A 2367/4885 |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | NPC1 3329/4885MAPT 3023/4885RAB9A 4088/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | NPC1 3255/4885MAPT 2314/4885RAB9A 2367/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | NPC1 3283/4885MAPT 2397/4885RAB9A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.